OCGN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.29%

Insider Buying (Last 12 Months): $9,100.00

Insider Selling (Last 12 Months): $0.00

Ocugen Insider Trading History Chart

Ocugen Share Price & Price History

^$0.77

▲ +0.0021 (0.27%)

As of 12/20/2024 06:45 PM ET

Days: 30 | 90 | 365

WARNING: “Buffett Indicator” flashing for first time in 50 years

From Behind the Markets | Ad

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Ocugen Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/26/2024	Prabhavathi Fernandes	Director	Buy	10,000	$0.91	$9,100.00	10,000
6/14/2023	Junge Zhang	Director	Buy	200,278	$0.50	$100,139.00	1,077,182
1/17/2023	Shankar Musunuri	CEO	Sell	100,000	$1.28	$128,000.00	2,227,950
10/14/2022	Shankar Musunuri	CEO	Sell	100,000	$1.66	$166,000.00	752,540
10/6/2022	Ramesh Kumar	Director	Sell	4,500	$1.83	$8,235.00
8/11/2022	Kirsten Castillo	Director	Sell	42,000	$2.91	$122,220.00	50,000
7/18/2022	Ramesh Kumar	Director	Sell	7,500	$2.57	$19,275.00
7/14/2022	Shankar Musunuri	CEO	Sell	150,000	$2.72	$408,000.00	752,540
5/13/2022	Shankar Musunuri	CEO	Sell	125,000	$1.92	$240,000.00	752,540
4/18/2022	Ramesh Kumar	Director	Sell	7,500	$2.83	$21,225.00
3/16/2022	Shankar Musunuri	CEO	Sell	81,823	$2.65	$216,830.95
1/18/2022	Ramesh Kumar	Director	Sell	7,500	$4.07	$30,525.00

AI breakthrough about to upend industry

From Porter & Company | Ad

Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

I urge you to watch it now.

SEC Filings (Institutional Ownership Changes) for Ocugen (NASDAQ:OCGN)

10.27% of Ocugen stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Ocugen Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/27/2024	Franklin Resources Inc.	149,217	$0.14M	0.0%	N/A	0.051%
11/19/2024	Barclays PLC	581,087	$0.58M	0.0%	+104.3%	0.199%
11/16/2024	Geode Capital Management LLC	6,278,554	$6.23M	0.0%	+6.3%	2.181%
11/15/2024	Barclays PLC	581,087	$0.58M	0.0%	+104.3%	0.202%
11/15/2024	XTX Topco Ltd	235,101	$0.23M	0.0%	N/A	0.082%
11/15/2024	Wellington Management Group LLP	459,102	$0.46M	0.0%	N/A	0.159%
11/15/2024	State Street Corp	15,824,517	$15.70M	0.0%	+7.1%	5.497%
11/14/2024	MetLife Investment Management LLC	89,508	$89K	0.0%	+36.4%	0.031%
11/9/2024	Intech Investment Management LLC	93,673	$93K	0.0%	N/A	0.033%
11/5/2024	GSA Capital Partners LLP	204,310	$0.20M	0.0%	N/A	0.071%
10/24/2024	NorthCrest Asset Manangement LLC	90,780	$90K	0.0%	N/A	0.035%
10/3/2024	SG Americas Securities LLC	88,096	$87K	0.0%	N/A	0.034%
8/15/2024	The Manufacturers Life Insurance Company	106,823	$0.17M	0.0%	N/A	0.042%
8/14/2024	Xponance Inc.	15,861	$25K	0.0%	N/A	0.006%
8/14/2024	Profund Advisors LLC	146,642	$0.23M	0.0%	N/A	0.057%
8/12/2024	E Fund Management Co. Ltd.	48,412	$75K	0.0%	N/A	0.019%
8/7/2024	Daiwa Securities Group Inc.	43,097	$67K	0.0%	N/A	0.017%
8/5/2024	Victory Capital Management Inc.	32,642	$51K	0.0%	N/A	0.013%
8/1/2024	Rhumbline Advisers	301,218	$0.47M	0.0%	+3,040.0%	0.117%
7/29/2024	Principal Financial Group Inc.	34,566	$54K	0.0%	-41.8%	0.013%
7/26/2024	Bank of New York Mellon Corp	751,819	$1.17M	0.0%	+2,760.5%	0.292%
7/17/2024	Baader Bank Aktiengesellschaft	22,550	$35K	0.0%	N/A	0.009%
5/17/2024	Tidal Investments LLC	66,009	$0.11M	0.0%	N/A	0.026%
5/15/2024	Lazard Asset Management LLC	43,019	$69K	0.0%	-35.6%	0.017%
5/10/2024	Vanguard Group Inc.	11,999,551	$19.68M	0.0%	-0.3%	4.663%
5/9/2024	State Board of Administration of Florida Retirement System	80,676	$0.13M	0.0%	N/A	0.031%
5/8/2024	Headlands Technologies LLC	40,198	$66K	0.0%	N/A	0.016%
4/29/2024	Principal Financial Group Inc.	59,354	$97K	0.0%	-13.3%	0.023%
4/23/2024	Truefg LLC	21,000	$34K	0.0%	N/A	0.008%
4/11/2024	David J Yvars Group	21,170	$35K	0.0%	N/A	0.008%
11/14/2023	Luminus Management LLC	2,722,656	$1.09M	0.3%	-33.3%	1.061%
10/24/2023	Bank of New York Mellon Corp	87,752	$35K	0.0%	-35.2%	0.034%
8/14/2023	Luminus Management LLC	4,079,238	$2.22M	0.7%	N/A	1.802%
7/27/2023	Virtu Financial LLC	220,686	$0.12M	0.0%	N/A	0.097%
5/9/2023	Y Intercept Hong Kong Ltd	221,791	$0.19M	0.0%	N/A	0.098%
4/28/2023	SG Americas Securities LLC	87,245	$74K	0.0%	+760.8%	0.039%
4/18/2023	ETF Managers Group LLC	73,601	$63K	0.0%	+34.9%	0.033%
3/23/2023	MetLife Investment Management LLC	70,923	$92K	0.0%	-37.0%	0.031%
2/9/2023	Citigroup Inc.	1,143,222	$1.49M	0.0%	-36.4%	0.522%
2/8/2023	UBS Group AG	1,572,040	$2.04M	0.0%	+444.8%	0.718%
2/8/2023	Swiss National Bank	522,900	$0.68M	0.0%	+3.0%	0.239%
2/7/2023	Mitsubishi UFJ Kokusai Asset Management Co. Ltd.	156,111	$0.20M	0.0%	+38.6%	0.071%
11/15/2022	ETF Managers Group LLC	63,907	$0.11M	0.0%	-60.7%	0.029%
11/15/2022	Bayesian Capital Management LP	23,000	$41K	0.0%	N/A	0.011%
11/15/2022	Buckingham Strategic Partners	15,500	$28K	0.0%	N/A	0.007%
11/14/2022	Point72 Hong Kong Ltd	76,013	$0.14M	0.0%	+155.1%	0.035%
11/14/2022	E Fund Management Co. Ltd.	132,938	$0.24M	0.0%	-16.3%	0.061%
11/10/2022	ExodusPoint Capital Management LP	45,521	$81K	0.0%	N/A	0.021%
11/10/2022	Tower Research Capital LLC TRC	126,465	$0.23M	0.0%	+82.2%	0.058%
11/7/2022	Virtu Financial LLC	87,150	$0.16M	0.0%	N/A	0.040%
11/3/2022	Teacher Retirement System of Texas	70,683	$0.13M	0.0%	+121.2%	0.033%
11/3/2022	Barclays PLC	1,202,242	$2.14M	0.0%	+8,751.7%	0.555%
11/2/2022	Victory Capital Management Inc.	24,098	$43K	0.0%	-71.8%	0.011%
10/31/2022	SG Americas Securities LLC	44,234	$79K	0.0%	-81.9%	0.020%
8/12/2022	Rafferty Asset Management LLC	1,385,734	$3.15M	0.0%	-36.5%	0.640%
8/11/2022	Alps Advisors Inc.	127,930	$0.29M	0.0%	N/A	0.059%
8/11/2022	JPMorgan Chase & Co.	3,294,268	$7.48M	0.0%	-18.0%	1.521%
8/9/2022	Swiss National Bank	507,600	$1.15M	0.0%	+7.8%	0.235%
8/4/2022	Mitsubishi UFJ Kokusai Asset Management Co. Ltd.	110,672	$0.25M	0.0%	N/A	0.051%
8/2/2022	Xponance Inc.	11,526	$26K	0.0%	N/A	0.005%
8/1/2022	Victory Capital Management Inc.	85,441	$0.19M	0.0%	-25.9%	0.040%
8/1/2022	ProShare Advisors LLC	24,045	$54K	0.0%	-30.6%	0.011%
7/29/2022	SG Americas Securities LLC	244,996	$0.56M	0.0%	+180.2%	0.114%
7/28/2022	Arizona State Retirement System	58,390	$0.13M	0.0%	+8.4%	0.027%
7/27/2022	Dynamic Advisor Solutions LLC	25,430	$58K	0.0%	-18.6%	0.012%
5/12/2022	E Fund Management Co. Ltd.	109,488	$0.36M	0.0%	+239.5%	0.051%
5/11/2022	GSA Capital Partners LLP	31,357	$0.10M	0.0%	+99.5%	0.015%
5/9/2022	Swiss National Bank	471,000	$1.55M	0.0%	+7.5%	0.218%
5/4/2022	Victory Capital Management Inc.	115,351	$0.25M	0.0%	+30.3%	0.058%
4/29/2022	SG Americas Securities LLC	87,423	$0.29M	0.0%	+304.5%	0.044%
4/11/2022	Dynamic Advisor Solutions LLC	31,230	$0.10M	0.0%	+122.6%	0.016%
2/15/2022	Southpoint Capital Advisors LP	1,354,710	$6.16M	0.1%	N/A	0.680%
2/14/2022	Point72 Hong Kong Ltd	73,683	$0.34M	0.0%	N/A	0.037%
2/14/2022	ETF Managers Group LLC	60,487	$0.29M	0.0%	N/A	0.030%
2/14/2022	GSA Capital Partners LLP	15,718	$72K	0.0%	N/A	0.008%
2/14/2022	Schroder Investment Management Group	358,908	$1.63M	0.0%	N/A	0.180%
2/11/2022	Ensign Peak Advisors Inc	54,570	$0.25M	0.0%	N/A	0.027%
2/10/2022	Rhumbline Advisers	193,340	$0.88M	0.0%	-1.4%	0.097%
2/10/2022	JPMorgan Chase & Co.	3,321,956	$15.12M	0.0%	+562.9%	1.668%
2/10/2022	Rafferty Asset Management LLC	985,645	$4.49M	0.0%	+126.2%	0.495%
2/10/2022	Citigroup Inc.	831,879	$3.79M	0.0%	+131.4%	0.418%
2/10/2022	Teacher Retirement System of Texas	37,678	$0.17M	0.0%	+24.4%	0.019%
2/10/2022	Buckingham Strategic Partners	14,000	$64K	0.0%	N/A	0.007%
2/9/2022	Principal Financial Group Inc.	55,190	$0.25M	0.0%	-27.5%	0.028%
2/9/2022	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	15,939	$73K	0.0%	N/A	0.008%
2/8/2022	ProShare Advisors LLC	40,344	$0.18M	0.0%	+70.5%	0.020%
2/8/2022	Northern Trust Corp	1,841,736	$8.38M	0.0%	-0.4%	0.925%
2/7/2022	SG Americas Securities LLC	21,612	$98K	0.0%	-69.3%	0.011%
2/3/2022	Advisor Group Holdings Inc.	17,926	$81K	0.0%	-50.7%	0.009%
2/3/2022	Nisa Investment Advisors LLC	13,000	$46K	0.0%	N/A	0.007%
2/1/2022	Landscape Capital Management L.L.C.	62,758	$0.29M	0.0%	N/A	0.032%
1/28/2022	Allspring Global Investments Holdings LLC	79,015	$0.36M	0.0%	N/A	0.040%
1/26/2022	Dynamic Advisor Solutions LLC	14,030	$64K	0.0%	-33.2%	0.007%
1/24/2022	Strs Ohio	24,800	$0.11M	0.0%	-42.1%	0.012%
1/21/2022	Russell Investments Group Ltd.	5,943	$27K	0.0%	-81.3%	0.003%
12/14/2021	UBS Asset Management Americas Inc.	186,155	$1.34M	0.0%	+5.2%	0.093%
12/8/2021	Moors & Cabot Inc.	25,000	$26K	0.0%	N/A	0.013%
11/19/2021	American International Group Inc.	101,070	$0.73M	0.0%	-2.3%	0.051%
11/17/2021	Centiva Capital LP	10,608	$76K	0.0%	N/A	0.005%
11/16/2021	Schonfeld Strategic Advisors LLC	51,800	$0.37M	0.0%	+78.0%	0.026%

Data available starting January 2016

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Today's Range

Now: $0.77

$0.73

$0.80

50 Day Range

MA: $0.92

$0.75

$1.08

52 Week Range

Now: $0.77

$0.37

$2.11

Volume

21,568,055 shs

Average Volume

6,006,622 shs

Market Capitalization

$224.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.82

Who are the company insiders with the largest holdings of Ocugen?: Ocugen's top insider shareholders include:
Shankar Musunuri (CEO)
Junge Zhang (Director)
Prabhavathi Fernandes (Director)
Learn More about top insider investors at Ocugen.
Who are the major institutional investors of Ocugen?: Ocugen's top institutional shareholders include:
State Street Corp — 5.50%
Geode Capital Management LLC — 2.18%
Barclays PLC — 0.20%
Barclays PLC — 0.20%
Wellington Management Group LLP — 0.16%
XTX Topco Ltd — 0.08%
Learn More about top institutional investors of Ocugen stock.
Which institutional investors are buying Ocugen stock?: During the last quarter, OCGN stock was purchased by institutional investors including:
State Street Corp
Wellington Management Group LLP
Geode Capital Management LLC
Barclays PLC
Barclays PLC
XTX Topco Ltd
GSA Capital Partners LLP
Franklin Resources Inc.
In the previous year, these company insiders have bought Ocugen stock:
Shankar Musunuri (CEO)
Junge Zhang (Director)
Learn More investors buying Ocugen stock.